dexchlorpheniramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4411	25523-97-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexchlorpheniramine (+)-Chloropheniramine (+)-Chlorpheniramine S-Chlorpheniramine d-Chlorpheniramine dexchlorpheniramine maleate	Molecular weight: 274.79 Formula: C16H19ClN2 CLOGP: 3.15 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 16.13 ALOGS: -3.72 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexchlorpheniramine
(+)-Chloropheniramine
(+)-Chlorpheniramine
S-Chlorpheniramine
d-Chlorpheniramine
dexchlorpheniramine maleate

Molecular weight: 274.79
Formula: C16H19ClN2
CLOGP: 3.15
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 16.13
ALOGS: -3.72
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
6	mg	O
6	mg	P

ADMET properties:

Property	Value	Reference
S (Water solubility)	3 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 14, 1981	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Erythema	336.00	26.91	231	7752	175520	63305519
Infusion related reaction	213.98	26.91	204	7779	245317	63235722
Cytokine release syndrome	159.47	26.91	62	7921	14252	63466787
Hepatocellular injury	153.70	26.91	73	7910	27308	63453731
Hypersensitivity	132.74	26.91	173	7810	292512	63188527
Anaphylactic shock	126.51	26.91	61	7922	23572	63457467
Febrile neutropenia	100.08	26.91	97	7886	118352	63362687
Pyrexia	96.72	26.91	194	7789	470284	63010755
Sense of oppression	91.43	26.91	22	7961	994	63480045
Oxygen saturation decreased	77.52	26.91	74	7909	88511	63392528
Rash maculo-papular	72.80	26.91	47	7936	31849	63449190
Fatigue	59.55	26.91	19	7964	888009	62593030
Dyspnoea	59.55	26.91	200	7783	661113	62819926
Neutrophil count decreased	56.83	26.91	51	7932	56355	63424684
Hyperthermia	56.24	26.91	26	7957	9130	63471909
Drug ineffective	53.39	26.91	33	7950	1044732	62436307
Lymphopenia	51.93	26.91	31	7952	18296	63462743
Chest discomfort	51.16	26.91	66	7917	109903	63371136
Hypotension	49.42	26.91	107	7876	272497	63208542
Bronchospasm	48.37	26.91	29	7954	17251	63463788
Febrile bone marrow aplasia	45.61	26.91	21	7962	7304	63473735
Serum sickness	45.10	26.91	16	7967	2844	63478195
Chills	43.54	26.91	62	7921	113316	63367723
Hypertension	42.16	26.91	102	7881	279201	63201838
Hepatic function abnormal	40.22	26.91	35	7948	37107	63443932
Cholestasis	38.64	26.91	31	7952	29403	63451636
Wrong patient received product	37.30	26.91	13	7970	2194	63478845
Pain	36.89	26.91	24	7959	740604	62740435
Neutropenia	35.51	26.91	72	7911	174933	63306106
Feeling hot	34.71	26.91	37	7946	50317	63430722
Tachycardia	34.61	26.91	57	7926	118099	63362940
Anaphylactoid reaction	34.05	26.91	14	7969	3709	63477330
Platelet count decreased	33.99	26.91	56	7927	116066	63364973
Cytomegalovirus infection	31.69	26.91	24	7959	20928	63460111
Organising pneumonia	31.16	26.91	15	7968	5761	63475278
Urticaria	31.04	26.91	66	7917	165736	63315303
Hypothermia	30.94	26.91	20	7963	13561	63467478
Psychiatric decompensation	30.57	26.91	10	7973	1391	63479648
Pruritus	30.31	26.91	107	7876	361346	63119693
Abdominal discomfort	29.64	26.91	3	7980	320882	63160157
Thrombocytopenia	29.25	26.91	61	7922	151096	63329943
Malaise	28.16	26.91	115	7868	415839	63065200
Anaphylactic reaction	28.13	26.91	38	7945	66062	63414977
Mixed liver injury	27.69	26.91	13	7970	4722	63476317
Persecutory delusion	27.26	26.91	11	7972	2779	63478260

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cytokine release syndrome	264.29	23.47	121	7932	22756	34926122
Febrile bone marrow aplasia	149.53	23.47	60	7993	8149	34940729
Infusion related reaction	146.72	23.47	111	7942	52946	34895932
Erythema	139.15	23.47	134	7919	88646	34860232
Febrile neutropenia	125.95	23.47	156	7897	136693	34812185
Pyrexia	114.46	23.47	242	7811	332771	34616107
Hypersensitivity	108.73	23.47	99	7954	60936	34887942
Neutropenia	74.47	23.47	131	7922	156647	34792231
Anaphylactic shock	74.06	23.47	46	8007	15895	34932983
Alveolar lung disease	72.41	23.47	17	8036	369	34948509
Pulmonary interstitial emphysema syndrome	67.25	23.47	17	8036	507	34948371
Generalised oedema	63.25	23.47	38	8015	12370	34936508
Hyperthermia	55.49	23.47	33	8020	10544	34938334
Fatigue	48.25	23.47	13	8040	370640	34578238
Fibrin D dimer increased	47.51	23.47	22	8031	4222	34944656
Chills	46.77	23.47	74	7979	80969	34867909
Diffuse alveolar damage	45.90	23.47	18	8035	2296	34946582
Interstitial lung disease	41.00	23.47	62	7991	65220	34883658
Face oedema	40.68	23.47	28	8025	11488	34937390
Hypotension	40.14	23.47	127	7926	221522	34727356
Hyperammonaemia	39.07	23.47	22	8031	6345	34942533
Sense of oppression	38.26	23.47	11	8042	538	34948340
Necrotising retinitis	37.70	23.47	12	8041	830	34948048
Kounis syndrome	37.67	23.47	16	8037	2502	34946376
Eosinophilia	36.16	23.47	37	8016	26185	34922693
Eosinophilic pneumonia	35.64	23.47	17	8036	3484	34945394
Drug ineffective	35.47	23.47	32	8021	456719	34492159
Rash maculo-papular	33.65	23.47	37	8016	28414	34920464
Platelet count decreased	31.88	23.47	79	7974	119638	34829240
Cardiac ventricular disorder	31.19	23.47	8	8045	253	34948625
Cytomegalovirus test positive	31.04	23.47	16	8037	3870	34945008
Disseminated intravascular coagulation	30.47	23.47	31	8022	21785	34927093
Neutrophil count decreased	29.92	23.47	47	8006	51057	34897821
Rash	29.37	23.47	115	7938	222637	34726241
Hypoxia	28.62	23.47	48	8005	55047	34893831
Abdominal compartment syndrome	28.41	23.47	10	8043	943	34947935
Acute coronary syndrome	28.11	23.47	24	8029	13521	34935357
Oxygen saturation decreased	28.11	23.47	47	8006	53771	34895107
Malaise	27.86	23.47	100	7953	185725	34763153
Cytomegalovirus infection	25.86	23.47	31	8022	26104	34922774
Septic shock	25.32	23.47	53	8000	71781	34877097
Hepatic function abnormal	24.86	23.47	40	8013	44323	34904555
Hepatic encephalopathy	24.49	23.47	23	8030	14662	34934216
Bronchospasm	24.31	23.47	20	8033	10711	34938167
Blood immunoglobulin G decreased	24.18	23.47	10	8043	1463	34947415
Eczema	23.59	23.47	25	8028	18411	34930467
Sepsis	23.57	23.47	88	7965	166473	34782405

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Erythema	426.25	19.69	356	15822	222934	79505276
Cytokine release syndrome	405.07	19.69	180	15998	35818	79692392
Infusion related reaction	337.10	19.69	316	15862	229921	79498289
Hypersensitivity	213.48	19.69	264	15914	261975	79466235
Febrile neutropenia	198.40	19.69	239	15939	230760	79497450
Pyrexia	188.59	19.69	420	15758	678289	79049921
Anaphylactic shock	174.53	19.69	102	16076	35894	79692316
Febrile bone marrow aplasia	152.41	19.69	67	16111	12953	79715257
Hepatocellular injury	139.01	19.69	98	16080	47495	79680715
Sense of oppression	120.58	19.69	33	16145	1533	79726677
Hyperthermia	103.26	19.69	57	16121	17980	79710230
Fatigue	100.61	19.69	32	16146	929695	78798515
Neutropenia	100.38	19.69	196	15982	287514	79440696
Rash maculo-papular	95.48	19.69	84	16094	55994	79672216
Chills	88.62	19.69	134	16044	160100	79568110
Oxygen saturation decreased	86.11	19.69	118	16060	128929	79599281
Neutrophil count decreased	80.07	19.69	97	16081	93862	79634348
Hypotension	75.57	19.69	228	15950	440089	79288121
Drug ineffective	74.77	19.69	66	16112	1080847	78647363
Toxicity to various agents	69.48	19.69	4	16174	421536	79306674
Pulmonary interstitial emphysema syndrome	69.42	19.69	17	16161	506	79727704
Alveolar lung disease	67.76	19.69	17	16161	560	79727650
Platelet count decreased	67.04	19.69	132	16046	194532	79533678
Hepatic function abnormal	61.50	19.69	75	16103	73032	79655178
Interstitial lung disease	59.16	19.69	92	16086	112508	79615702
Bronchospasm	56.40	19.69	44	16134	24815	79703395
Pain	50.95	19.69	41	16137	703761	79024449
Serum sickness	49.91	19.69	21	16157	3645	79724565
Dyspnoea	49.75	19.69	320	15858	856705	78871505
Hypertension	48.99	19.69	163	16015	330829	79397381
Fibrin D dimer increased	48.57	19.69	27	16151	8627	79719583
Cytomegalovirus infection	48.19	19.69	51	16127	42593	79685617
Face oedema	47.57	19.69	42	16136	28094	79700116
Generalised oedema	47.47	19.69	39	16139	23670	79704540
Thrombocytopenia	45.99	19.69	138	16040	265121	79463089
Tumour lysis syndrome	45.07	19.69	38	16140	23901	79704309
Malaise	43.89	19.69	206	15972	489663	79238547
White blood cell count decreased	43.65	19.69	109	16069	188179	79540031
Pruritus	42.19	19.69	175	16003	394473	79333737
Urticaria	41.66	19.69	106	16072	185095	79543115
Septic shock	40.70	19.69	82	16096	122719	79605491
Anaphylactic reaction	40.63	19.69	66	16112	83677	79644533
Diffuse alveolar damage	40.40	19.69	18	16160	3586	79724624
Feeling hot	40.37	19.69	55	16123	59679	79668531
Hyperammonaemia	39.89	19.69	26	16152	11067	79717143
Anaphylactoid reaction	39.12	19.69	20	16158	5402	79722808
Enterocolitis	38.03	19.69	28	16150	14484	79713726
Hypoxia	37.93	19.69	72	16106	103171	79625039
Immune effector cell-associated neurotoxicity syndrome	37.69	19.69	20	16158	5828	79722382
Cytomegalovirus test positive	37.38	19.69	20	16158	5927	79722283
Eosinophilia	37.28	19.69	46	16132	45299	79682911
Disseminated intravascular coagulation	37.22	19.69	41	16137	35801	79692409
Lymphopenia	37.13	19.69	38	16140	30519	79697691
Arthralgia	36.92	19.69	37	16141	571766	79156444
Drug intolerance	36.80	19.69	5	16173	264114	79464096
Product dose omission issue	36.16	19.69	4	16174	247533	79480677
Acute coronary syndrome	34.64	19.69	31	16147	21102	79707108
Hypothermia	34.61	19.69	32	16146	22714	79705496
Necrotising retinitis	34.59	19.69	12	16166	1233	79726977
Kounis syndrome	34.43	19.69	17	16161	4265	79723945
Chest discomfort	34.19	19.69	82	16096	137962	79590248
Dizziness	34.05	19.69	34	16144	526407	79201803
Pain in extremity	33.57	19.69	16	16162	364522	79363688
Upper respiratory tract inflammation	32.39	19.69	16	16162	4019	79724191
Abdominal discomfort	32.10	19.69	6	16172	250721	79477489
Sepsis	31.57	19.69	123	16055	269305	79458905
Eosinophilic pneumonia	30.99	19.69	17	16161	5293	79722917
Weight increased	30.85	19.69	9	16169	277377	79450833
Swelling	30.43	19.69	4	16174	216707	79511503
Tachycardia	30.32	19.69	92	16086	177676	79550534
Cardiac ventricular disorder	29.51	19.69	8	16170	358	79727852
Mucosal inflammation	29.36	19.69	54	16124	75526	79652684
Rash	26.96	19.69	205	15973	578153	79150057
Lung disorder	26.93	19.69	54	16124	80503	79647707
Condition aggravated	26.40	19.69	38	16140	501086	79227124
Oropharyngeal discomfort	26.27	19.69	17	16161	7149	79721061
Cyanosis	24.76	19.69	28	16150	25154	79703056
Abdominal compartment syndrome	24.62	19.69	10	16168	1587	79726623
Sinusitis	24.34	19.69	5	16173	195496	79532714
Hyperamylasaemia	24.13	19.69	9	16169	1138	79727072
Erythema multiforme	23.37	19.69	23	16155	17628	79710582
Hepatitis	23.15	19.69	41	16137	55686	79672524
Therapeutic product effect decreased	23.06	19.69	3	16175	163860	79564350
Cholestasis	22.51	19.69	39	16139	52070	79676140
Wrong patient received product	22.13	19.69	13	16165	4605	79723605
Aspartate aminotransferase increased	22.01	19.69	70	16108	138571	79589639
Organising pneumonia	21.91	19.69	18	16160	10921	79717289
Contraindicated product administered	21.89	19.69	3	16175	157535	79570675
Drug reaction with eosinophilia and systemic symptoms	21.39	19.69	43	16135	64201	79664009
Larynx irritation	21.18	19.69	5	16173	127	79728083
Hepatic encephalopathy	20.64	19.69	25	16153	24141	79704069
Palmar-plantar erythrodysaesthesia syndrome	20.13	19.69	29	16149	33105	79695105
Type I hypersensitivity	20.08	19.69	12	16166	4386	79723824
Hot flush	19.81	19.69	38	16140	54839	79673371

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AB02	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
ATC	R06AB52	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dermatographic urticaria	indication	7632005	DOID:743
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic rhinitis	indication	61582004
Urticaria	indication	126485001
Seasonal allergic rhinitis	indication	367498001
Itching of skin	indication	418363000
Allergic conjunctivitis	indication	473460002	DOID:11204
Brain damage	contraindication	2470005
Ocular hypertension	contraindication	4210003	DOID:9282
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Dependent drug abuse	contraindication	6525002
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Alcohol withdrawal delirium	contraindication	8635005
Peptic ulcer	contraindication	13200003	DOID:750
Asthenia	contraindication	13791008
Severe chronic ulcerative colitis	contraindication	14311001
Constipation	contraindication	14760008	DOID:2089
Chronic disease of respiratory system	contraindication	17097001
Mood swings	contraindication	18963009
Myocardial infarction	contraindication	22298006	DOID:5844
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Ventricular tachycardia	contraindication	25569003
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hypercapnia	contraindication	29596007
Dehydration	contraindication	34095006
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Acidosis	contraindication	51387008
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Arterial thrombosis	contraindication	65198009
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Poisoning by acetaminophen	contraindication	70273001
Arteriosclerotic vascular disease	contraindication	72092001
Diabetes mellitus	contraindication	73211009	DOID:9351
Urethral stricture	contraindication	76618002
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Chronic idiopathic constipation	contraindication	82934008
Cor pulmonale	contraindication	83291003	DOID:8515
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Pulmonary emphysema	contraindication	87433001
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Acute abdominal pain	contraindication	116290004
Procedure on urinary system	contraindication	118677009
Gastrointestinal obstruction	contraindication	126765001
Neoplasm of brain	contraindication	126952004	DOID:1319
Seizure disorder	contraindication	128613002
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Drug-induced psychosis	contraindication	191483003	DOID:1742
Partial atrioventricular block	contraindication	195039008
Acute pancreatitis	contraindication	197456007	DOID:2913
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Morbid obesity	contraindication	238136002	DOID:11981
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Drowsy	contraindication	271782001
Exacerbation of asthma	contraindication	281239006
Lesion of brain	contraindication	301766008
Coma	contraindication	371632003
Primary adrenocortical insufficiency	contraindication	373662000
Operation on gastrointestinal tract	contraindication	386621005
Hypoxia	contraindication	389086002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Central nervous system depression	contraindication	418072004
Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	422681000
Dysfunction of sphincter of Oddi	contraindication	430887001
Hypertensive urgency	contraindication	443482000
Acute exacerbation of asthma	contraindication	708038006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	Basic
pKa2	4.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.14	CHEMBL	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.16	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	7.89	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.31	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.98	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.92	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.68	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.09	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.48	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.60	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.26	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.56	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.13	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.13	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	4.78	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.12	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.07	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	4.93	DRUG MATRIX

External reference:

ID	Source
D07803	KEGG_DRUG
4019712	VUID
N0000147804	NUI
2438-32-6	SECONDARY_CAS_RN
4018792	VANDF
4019712	VANDF
C0057606	UMLSCUI
CHEBI:4464	CHEBI
CHEMBL1201353	ChEMBL_ID
CHEMBL1200927	ChEMBL_ID
DB13679	DRUGBANK_ID
C018904	MESH_SUPPLEMENTAL_RECORD_UI
1210	IUPHAR_LIGAND_ID
955	INN_ID
3Q9Q0B929N	UNII
33036	PUBCHEM_CID
DB09555	DRUGBANK_ID
22697	RXNORM
1479	MMSL
4556	MMSL
d00784	MMSL
003393	NDDF
004796	NDDF
16031005	SNOMEDCT_US
372663001	SNOMEDCT_US
68680008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RYMED	HUMAN OTC DRUG LABEL	2	0485-0080	TABLET, COATED	2 mg	ORAL	OTC monograph final	16 sections
RYMED	HUMAN OTC DRUG LABEL	2	0485-0080	TABLET, COATED	2 mg	ORAL	OTC monograph final	16 sections
RYCLORA	HUMAN PRESCRIPTION DRUG LABEL	1	15370-150	LIQUID	2 mg	ORAL	ANDA	13 sections
Polytussin DM	HUMAN OTC DRUG LABEL	3	50991-492	SYRUP	1 mg	ORAL	OTC monograph final	13 sections
ABATUSS DMX	HUMAN OTC DRUG LABEL	3	52083-625	LIQUID	1 mg	ORAL	OTC monograph final	10 sections
ABATUSS DMX	HUMAN OTC DRUG LABEL	3	52083-625	LIQUID	1 mg	ORAL	OTC monograph final	10 sections
DELTUSS DMX Cough Suppressant Nasal Decongestant Antihistamine GRAPE Flavor	HUMAN OTC DRUG LABEL	3	58238-225	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
DELTUSS DP Nasal Decongestant Antihistamine CHERRY Flavor	HUMAN OTC DRUG LABEL	2	58238-226	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
VANACOF	HUMAN OTC DRUG LABEL	3	58809-999	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
VANACOF	HUMAN OTC DRUG LABEL	3	58809-999	LIQUID	1 mg	ORAL	OTC monograph final	16 sections
Rescon	HUMAN OTC DRUG LABEL	2	64543-097	TABLET, MULTILAYER	2 mg	ORAL	OTC monograph final	15 sections
POLMON	HUMAN PRESCRIPTION DRUG LABEL	1	64543-600	SOLUTION	2 mg	ORAL	ANDA	14 sections
POLMON	HUMAN PRESCRIPTION DRUG LABEL	1	64543-600	SOLUTION	2 mg	ORAL	ANDA	14 sections
Dexchlorpheniramine Maleate, Phenylephrine HCl	HUMAN OTC DRUG LABEL	2	66576-080	TABLET	2 mg	ORAL	OTC monograph final	8 sections
PRO-REDAC	HUMAN OTC DRUG LABEL	3	66594-499	SYRUP	1 mg	ORAL	OTC monograph final	16 sections
chlophedianol hydrochloride, dexchlorpheniramine maleate, and pseudoephedrine hydrochloride	HUMAN OTC DRUG LABEL	3	69367-183	LIQUID	1 mg	ORAL	OTC MONOGRAPH FINAL	17 sections
WesTussin DM	HUMAN OTC DRUG LABEL	3	69367-334	SYRUP	1 mg	ORAL	OTC MONOGRAPH FINAL	17 sections